Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Zealand invests to boost number of smear tests:

This article was originally published in Clinica

Executive Summary

New Zealand is investing NZ$2.5m (US$1.8m) in an awareness drive aimed at increasing the number of women having cervical smears and to encourage regular testing in the 20-70 year age range. Prime Minister Helen Clark said that early detection through smears was the main reason behind a significant reduction in cervical cancer deaths in New Zealand - from 180 per year 10 years ago, to 70. Screening reduces the risk of developing cervical cancer by 90%, according to the national screening unit. The disease is treatable if caught early enough, but the catch is that it usually has no symptoms. The awareness campaign is targeted mainly at Maori and Pacific Island women, who have the lowest screening and the highest incidence rates of cervical cancer in New Zealand, but is also expected to encourage women in the wider population who have not been screened in the last three years, to come forward.

You may also be interested in...

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts